Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

HEL/ORNAV stock hub

HEL/ORNAV has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HEL/ORNAVis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

9.7B

Nasdaq Helsinki

Market data

Live price

Current market quote for this ticker.

Current price

HEL/ORNAV

In the news

Latest news · HEL/ORNAV

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E15.9

P25 10.8P50 15.9P75 16

Trailing P/E18.2

P25 13.1P50 18.2P75 20.9

ROE48.4

P25 -27.3P50 13.7P75 20.2

ROIC39.7

P25 -16.4P50 6.7P75 14.6

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HEL/ORNAV market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

238

Groups with data

Currency

EUR

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Finland
Country code	FI
Employees	4,132
Employees Change	189%
Employees Change Percent	4.79
Enterprise value	EUR 9.8B
Exchange	Nasdaq Helsinki
Financial currency	EUR
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	FI0009014369
Last refreshed	2026-05-10
Market cap	EUR 9.7B
Price	EUR 68.5
Price currency	EUR
Rev Per Employee	472,555.66x
Sector	Healthcare
Sic	2834
Symbol	hel/ORNAV
Website	https://www.orionpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.48%
EV Earnings	18.48x
EV/EBIT	14.63x
EV/EBITDA	13.46x
EV/FCF	48.93x
EV/Sales	5.01x
FCF yield	2.07%
Forward P/E	15.87x
P/B ratio	8.6x
P/E ratio	18.24x
P/S ratio	4.94x
PE Ratio10 Y	22.42x
PE Ratio3 Y	22.5x
PE Ratio5 Y	23.19x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	34.25%
EBITDA Margin	36.91%
FCF margin	10.24%
Gross margin	64.8%
Gross Profit	EUR 1.3B
Gross Profit Growth	29.42%
Gross Profit Growth Q	25.87%
Gross Profit Growth3 Y	14.51%
Gross Profit Growth5 Y	15.17%
Net Income	EUR 529.4M
Net Income Growth	52.39%
Net Income Growth Q	47.47%
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Net Income Growth3 Y	16.36%
Net Income Growth5 Y	20.07%
Pretax Margin	34.02%
Profit Margin	27.11%
Profit Per Employee	EUR 128,122
Profitable Years	22
ROA	22.11
Roa5y	16.95
ROCE	52.22
ROE	48.36
Roe5y	34.21
ROIC	39.73
Roic5y	35.26

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	12.68%
Cagr15y	14.53%
Cagr1y	25.51%
Cagr3y	19.94%
Cagr5y	16.83%
Div CAGR10	1.51%
Div CAGR3	30.5%
Div CAGR5	3.71%
EPS Growth	52.06
EPS Growth Q	46.74
EPS Growth Quarters	2
EPS Growth Years	2
EPS Growth3 Y	16.29
EPS Growth5 Y	20.17
FCF Growth	-1.04%
FCF Growth Q	-67.5%
FCF Growth3 Y	-16.6%
FCF Growth5 Y	-4.43%
OCF Growth	5.98%
OCF Growth Q	-52.2%
OCF Growth10 Y	1.23%
OCF Growth3 Y	-11.96%
OCF Growth5 Y	-0.51%
Revenue Growth	22.92x
Revenue Growth Q	17.8x
Revenue Growth Quarters	2x
Revenue Growth Years	2x
Revenue Growth3 Y	13.15x
Revenue Growth5 Y	12.85x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 1.03
Assets	EUR 2.1B
Cash	EUR 199.3M
Current Assets	EUR 1.4B
Current Liabilities	EUR 798.6M
Debt	EUR 330.3M
Debt EBITDA	EUR 0.45
Debt Equity	EUR 0.29
Debt FCF	EUR 1.65
Equity	EUR 1.1B
Interest Coverage	77.76
Liabilities	EUR 956.7M
Long Term Assets	EUR 667.9M
Long Term Liabilities	EUR 158.1M
Net Cash	EUR -131M
Net Cash By Market Cap	EUR -1.36
Net Debt EBITDA	EUR 0.18
Net Debt Equity	EUR 0.12
Net Debt FCF	EUR 0.66
Tangible Book Value	EUR 933.1M
Tangible Book Value Per Share	EUR 6.62
WACC	5.6

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.77
Inventory Turnover	1.45
Net Working Capital	EUR 633M
Quick ratio	1.13
Working Capital	EUR 612.6M
Working Capital Turnover	EUR 2.77

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.1%
Dividend Growth	9.76%
Dividend Growth Years	3%
Dividend per share	EUR 1.8
Dividend Years	20
Dividend Yield	2.63%
Ex Div Date	2026-10-19
Last Dividend	EUR 0.9
Payout Frequency	Semi-Annual
Payout Ratio	47.88%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	229.87%
1Y total return	25.49%
200-day SMA	66.72
3Y total return	72.57%
50-day SMA	69.57
50-day SMA vs 200-day SMA	50over200
5Y total return	117.67%
All Time High	75.1
All Time High Change	-8.79%
All Time High Date	2026-04-20
All Time Low	10.42
All Time Low Change	557.39%
All Time Low Date	2009-03-30
ATR	1.81
Beta	0.27
Ch YTD	8.22
High	69.5
High52	75.1
High52 Date	2026-04-20
High52ch	-8.79%
Low	68.3
Low52	51.6
Low52 Date	2025-05-12
Low52ch	32.75%
Ma50ch	-1.53%
Price vs 200-day SMA	2.67%
RSI	45.28
RSI Monthly	65.9
RSI Weekly	52.02
Sharpe ratio	0.75x
Sortino ratio	1.24
Total Return	2.48%
Tr YTD	9.68
Tr15y	665.49%
Tr1m	-3.79%
Tr1w	-0.72%
Tr3m	-5.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 668.7M
Operating Income Growth	40.28
Operating Income Growth Q	47.43
Operating Income Growth3 Y	16.51
Operating Income Growth5 Y	19.86
Operating margin	34.25

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	123,112,532%
Net Borrowing	-3,000,000
Shares Insiders	8.75%
Shares Institutions	38.68%
Shares Qo Q	-0.05%
Shares Yo Y	0.1%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 200M
Average Volume	10,480.7x
Bv Per Share	7.97
CAPEX	EUR -76.4M
Ch10y	132.2
Ch15y	301.5
Ch1m	-3.79
Ch1w	-0.72
Ch1y	22.32
Ch3m	-6.68
Ch3y	59.12
Ch5y	86.4
Ch6m	20.18
Change	-1.72%
Change From Open	-1.44
Close	69.7
Days Gap	-0.29
Depreciation Amortization	52,100,000
Dollar Volume	190,567
Earnings Date	2026-04-23
EBIT	EUR 668.7M
EBITDA	EUR 720.8M
EPS	EUR 3.76
F Score	6
FCF	EUR 200M
FCF EV Yield	2.04x
Financing CF	-234,000,000
Fiscal Year End	December
Founded	1,917
Goodwill	87,200,000
Graham Number	25.94206
Graham Upside	-62.13
Income Tax	EUR 134.9M
Investing CF	-102,600,000
Is Primary Listing	0
Last Earnings Date	2026-04-23
Last Report Date	2026-03-31
Lynch Fair Value	EUR 75.4
Lynch Upside	10.07
Ma150	66.51
Ma150ch	2.99%
Ma20	70.71
Ma20ch	-3.13%
Net CF	-60,100,000
Next Earnings Date	2026-07-17
Open	69.5
P FCF Ratio	48.27
P OCF Ratio	34.93
Payment Date	2026-10-27
Position In Range	16.67
Ppne	458,200,000
Price Date	2026-05-08
Price EBITDA	EUR 13.39
Ptbv Ratio	10.35
Relative Volume	0.26x
Revenue	1,952,600,000x
Tax By Revenue	6.91x
Tax Rate	20.31%
Tr6m	21.8%
Volume	2,782
Z Score	8.69

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

HEL/ORNAV dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.6%

$1.80 annual per share

Payout ratio

+47.9%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+3.7%

3 consecutive years of growth

Total shareholder yield

+2.5%

Next ex-dividend date: 2026-10-19

Performance

HEL/ORNAV stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HEL/ORNAV?

Insider, institutional, and short-interest positioning.

Institutional ownership

+38.7%

Share of float held by funds and institutions

Insider ownership

+8.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.1%

Negative means the company is buying back shares.

Technical

HEL/ORNAV momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.3

Neutral momentum band

Price vs 200-day MA

+2.7%

50/200-day relationship not available

Beta (5Y)

0.27

Less volatile than the market

Sharpe ratio

0.75

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HEL/ORNAV

Hub-level FAQ points readers to the deeper analysis pages.

What is the current hel/ORNAV stock rating?

hel/ORNAV is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full hel/ORNAV analysis?

The full report lives at /stocks/hel/ORNAV/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for hel/ORNAV?

The latest report frames hel/ORNAV around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the hel/ORNAV page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.